Monoclonal Antibodies in Veterinary Health Market Size Worth $3,425.91 Million By 2032 | CAGR: 15.98%

Monoclonal Antibodies in Veterinary Health Market Size Worth $3,425.91 Million By 2032 | CAGR: 15.98%

The global monoclonal antibodies in veterinary health market size is expected to reach USD 3,425.91 million by 2032, according to a new study by Polaris Market Research. The report “Monoclonal Antibodies in Veterinary Health Market Share, Size, Trends, Industry Analysis Report, By Animal Type (Dogs, Others); By Application (Dermatology, Pain, Others); By End-Use; By Region; Segment Forecast, 2023 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The market is being driven by factors such as the increasing prevalence of chronic diseases in companion animals, such as cancer and autoimmune disorders, which are being treated with mAb-based therapies due to their targeted approach and fewer side effects compared to traditional treatments. The rising pet adoption rate also creates a larger market for veterinary health products and services, including mAb treatments. This trend is expected to continue as more people adopt pets and seek high-quality healthcare services for their furry friends.

In addition to these factors, increasing research and development spending by industry players for the development of cancer treatments is anticipated to support market expansion over the forecast period. The increasing focus on zoonotic diseases, which can be transmitted between animals and humans, also drives a greater emphasis on animal health and disease prevention, potentially increasing demand for mAb-based treatments. Furthermore, developing novel mAb therapies and their approvals by regulatory authorities are expected to drive market growth as more effective treatments become available, expanding the range of applications for mAbs in veterinary health.

Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below:

Monoclonal antibodies (mAbs) are increasingly used in veterinary medicine, particularly in treating cancer in companion animals such as dogs, cats, and horses. mAbs can target specific cancer cells, providing a potentially less toxic and more effective alternative to traditional chemotherapy. While the increasing availability of mAbs for veterinary use is a promising trend, regulatory challenges and high costs remain a concern for veterinarians and pet owners. Nonetheless, as more mAbs become available and competition increases, prices will likely decrease over time, making this advanced treatment more accessible to those with limited financial resources.

Monoclonal Antibodies in Veterinary Health Market Report Highlights

  • The dogs segment accounted for the highest revenue share in 2022 due to the growing number of pet dogs and their expensive healthcare, driven by the rising prevalence of chronic diseases and pet insurance adoption.
  • The dermatology segment held the largest revenue share of the market due to the rising incidence of dermatological diseases like fleas, ticks, and allergic dermatitis, with allergies, otitis externa, surface pyoderma, and seborrheic dermatitis being the most commonly diagnosed conditions.
  • The veterinary hospitals segment dominated the market in revenue share due to the increasing number of veterinary hospitals and veterinarians, generating significant revenue through innovative therapies.
  • North America dominated the global market in 2022 due to government and corporate sector initiatives, pet insurance's increasing popularity, and key market players' presence in the region.
  • The global key market players include Adivo GmbH, Bayer Animal Health, Boehringer Ingelheim GmbH, Elanco; Indian Immunologicals Ltd., Invetx, Kindred Biosciences, Inc., Merck & Co. Inc, Nextmune, Virbac, Zoetis.

Polaris Market Research has segmented the Monoclonal Antibodies in Veterinary Health market report based on animal type, application, end-use, and region:

Monoclonal Antibodies in Veterinary Health, Animal Type Outlook (Revenue - USD Million, 2019 - 2032)

  • Dogs
  • Others

Monoclonal Antibodies in Veterinary Health, Application Outlook (Revenue - USD Million, 2019 - 2032)

  • Dermatology
  • Pain
  • Others

Monoclonal Antibodies in Veterinary Health, End-Use Outlook (Revenue - USD Million, 2019 - 2032)

  • Veterinary Hospitals
  • Others

Monoclonal Antibodies in Veterinary Health, Regional Outlook (Revenue - USD Million, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa